Douglas Miehm
Stock Analyst at RBC Capital
(3.14)
# 1,129
Out of 5,162 analysts
60
Total ratings
50%
Success rate
2.01%
Average return
Main Sectors:
Stocks Rated by Douglas Miehm
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MNKD MannKind | Downgrades: Sector Perform | $7.5 → $3.5 | $2.82 | +24.11% | 5 | Feb 27, 2026 | |
| LGND Ligand Pharmaceuticals | Maintains: Outperform | $234 → $235 | $211.48 | +11.12% | 8 | Dec 10, 2025 | |
| BLCO Bausch + Lomb | Maintains: Outperform | $17 → $19 | $16.58 | +14.60% | 14 | Nov 14, 2025 | |
| AUPH Aurinia Pharmaceuticals | Downgrades: Sector Perform | $9 → $15 | $14.37 | +4.38% | 11 | Nov 5, 2025 | |
| BHC Bausch Health Companies | Maintains: Sector Perform | $8.5 → $10 | $5.05 | +98.02% | 21 | May 2, 2025 | |
| ONCY Oncolytics Biotech | Maintains: Outperform | $6 → $5 | $0.96 | +420.02% | 1 | Mar 10, 2025 |
MannKind
Feb 27, 2026
Downgrades: Sector Perform
Price Target: $7.5 → $3.5
Current: $2.82
Upside: +24.11%
Ligand Pharmaceuticals
Dec 10, 2025
Maintains: Outperform
Price Target: $234 → $235
Current: $211.48
Upside: +11.12%
Bausch + Lomb
Nov 14, 2025
Maintains: Outperform
Price Target: $17 → $19
Current: $16.58
Upside: +14.60%
Aurinia Pharmaceuticals
Nov 5, 2025
Downgrades: Sector Perform
Price Target: $9 → $15
Current: $14.37
Upside: +4.38%
Bausch Health Companies
May 2, 2025
Maintains: Sector Perform
Price Target: $8.5 → $10
Current: $5.05
Upside: +98.02%
Oncolytics Biotech
Mar 10, 2025
Maintains: Outperform
Price Target: $6 → $5
Current: $0.96
Upside: +420.02%